Skip to main content
Clinical Trials/NCT03390985
NCT03390985
Completed
Not Applicable

Canadian Observation Trial in CF Patients Undergoing Treatment With Ivacaftor

Tanja Gonska0 sites18 target enrollmentApril 23, 2013
ConditionsCystic Fibrosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cystic Fibrosis
Sponsor
Tanja Gonska
Enrollment
18
Primary Endpoint
Functional in vivo test: Beta-adrenergic sweat secretion test
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Specific aims:

  1. To elucidate the biological mechanism that leads to pulmonary and nutritional improvement in CF patients following treatment with ivacaftor using advanced techniques to assess changes of the pulmonary and nutritional status
  2. To examine the relation between the individual response to ivacaftor and the presence of modifier genes associated with CF disease severity,
  3. To assess altered CFTR function using new available in vivo tests,
  4. To validate newly developed in vivo sweat tests with well established functional tests,
  5. To establish correlation between the CFTR response to Vx-770 measured in a new ex vivo method (organoids) and the actual clinical and/or functional response in individual patients,
  6. To examine response in other CF-specific features such as aqua wrinkling.
  7. To examine if sleep/activity level changes.
  8. To establish a biorepository to enable further investigations.
Registry
clinicaltrials.gov
Start Date
April 23, 2013
End Date
July 26, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Tanja Gonska
Responsible Party
Sponsor Investigator
Principal Investigator

Tanja Gonska

Principal Investigator

The Hospital for Sick Children

Eligibility Criteria

Inclusion Criteria

  • any patient being prescribed ivacaftor

Exclusion Criteria

  • only relates to specific tests

Outcomes

Primary Outcomes

Functional in vivo test: Beta-adrenergic sweat secretion test

Time Frame: 7 study visits over a 2 year period

The beta-adrenergic sweat secretion test is measured as ratio of beta-adrenergic/cholinergic sweat secretion as difference between post and pre-drug start

Functional in vitro test: Rectal tissue biopsies to measure CFTR function in vitro using Ussing chamber studies and organoids

Time Frame: one study visit

Rectal tissue specimen is being used to measure the response to ivcaftor of individual CF patients in vitro

Functional in vitro test: Collect nasal brushes for CFTR to generate nasal cell cultures for the assessment of ivacaftor response and CFTR function

Time Frame: 2 study visits in 6 months

Nasal cultures are used to measure the response to ivcaftor in vitro as difference of the forskolin-induced response of CFTR to ivacaftor

Functional in vivo Cystic fibrosis transmembrane conductor regulator (CFTR) tests: Nasal Potential difference (NPD) measurements

Time Frame: 7 study visits over a 2 year period

NPD is measured to assess CFTR function as difference in mV between post and pre-drug start

Secondary Outcomes

  • Measurements of the pancreas function using fecal elastase test(4 study visits in 2 years)
  • Measurements of the lung clearance index(5 study visits in 1 year)
  • Assessment of pulmonary radiological changes using high resolution CT(4 study visits in 2 years)
  • Measurements of the pancreas function using serum trypsinogen(4 study visits in 2 years)
  • Measurements of the resting energy expenditure(4 study visits in 2 years)
  • Measurement of aqua wrinkling(2 study visits in 3 months)
  • Assessment of the nutritional status(4 study visits in 2 years)
  • Measurement of exhaled fractionated nitrogen oxide (FeNo)(5 study visits in 1 year)
  • Assessment of glucose tolerance(4 study visits in 2 years)

Similar Trials